Deerfield Management Company, L.P. (Series C) Fusion Pharmaceuticals Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.48 - $9.65 $8.87 Million - $34.5 Million	3,578,000 Added 126.74%	6,401,000 $61.5 Million
Q1 2023 May 15, 2023	BUY	$3.03 - $5.13 $8.55 Million - $14.5 Million	2,823,000 New	2,823,000 $10.6 Million
Q1 2021 May 17, 2021	SELL	$9.75 - $13.09 $1.58 Million - $2.13 Million	-162,378 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$11.5 - $13.73 $9.31 Million - $11.1 Million	-809,668 Reduced 83.3%	162,378 $1.91 Million
Q3 2020 Nov 16, 2020	SELL	$11.8 - $17.1 $3.36 Million - $4.87 Million	-284,954 Reduced 22.67%	972,046 $11.7 Million
Q2 2020 Aug 14, 2020	BUY	$17.0 - $17.78 $21.4 Million - $22.3 Million	1,257,000 New	1,257,000 $22 Million

Others Institutions Holding FUSN

# of Institutions

Shares Held

93K

Call Options Held

1.4K

Put Options Held

View Full List

About Fusion Pharmaceuticals Inc.

Ticker FUSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,390,500
Description
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order ...

More about FUSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account